Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 9/20 | 0.65 |
| ▸ | CLK1 | P49759 | 8/20 | 0.65 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.58 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.58 |
| ▸ | PLCG1 | P19174 | 2/20 | 0.57 |
| ▸ | KIT | P10721 | 1/20 | 0.57 |
| ▸ | IGF1R | P08069 | 1/20 | 0.56 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.56 |
| ▸ | NEK1 | Q96PY6 | 2/20 | 0.55 |
| ▸ | AXL | P30530 | 1/20 | 0.55 |
| ▸ | CDK8 | P49336 | 1/20 | 0.55 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.55 |
| ▸ | SGK1 | O00141 | 1/20 | 0.55 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.53 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.53 |
| ▸ | CDK2 | P24941 | 1/20 | 0.53 |
| ▸ | CDK9 | P50750 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8939991 | 0.82 | CDK2 (0.66) | DYRK1ACLK1PIK3CANTRK1KIT | |
| SCHEMBL8941190 | 0.82 | JAK2 (0.68) | DYRK1ACLK1NTRK1IGF1RRIPK1 | |
| SCHEMBL14319049 | 0.82 | DYRK1A (0.66) | DYRK1ACLK1PIK3CANTRK1PLCG1 | |
| SCHEMBL8939801 | 0.82 | CLK4 (0.72) | DYRK1ACLK1PIK3CANTRK1KIT | |
| SCHEMBL3768165 | 0.79 | NTRK1 (0.79) | DYRK1ACLK1PIK3CANTRK1PLCG1 | |
| SCHEMBL4171362 | 0.78 | NTRK1 (0.70) | DYRK1APIK3CANTRK1KITNEK1 | |
| SCHEMBL8941520 | 0.76 | JAK2 (0.68) | DYRK1ACLK1NTRK1IGF1RRIPK1 | |
| SCHEMBL3761694 | 0.75 | NTRK1 (0.84) | DYRK1ACLK1PIK3CANTRK1PLCG1 | |
| SCHEMBL26175478 | 0.75 | KIT (0.67) | DYRK1APIK3CANTRK1PLCG1KIT | |
| SCHEMBL12572864 | 0.75 | KIT (0.64) | DYRK1APIK3CANTRK1PLCG1KIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8188281-B2 | Azaindoles useful as inhibitors of JAK and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-05-29 | — | — | US | disclosed |
| US-20090176763-A1 | Azaindoles useful as inhibitors of JAK and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2009-07-09 | — | — | US | disclosed |
| US-7507826-B2 | Such as 3-(2-Methanesulfonyl-pyrimidin-4-yl)-5-pyridin-3-yl-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine; heart disease, diabetes, Alzheimer's disease, immunodeficiency disorders, inflammatory diseases, hypertension, allergic diseases, autoimmune diseases, destructive bone disorders | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-03-24 | — | — | US | disclosed |
| US-20070043063-A1 | Such as 3-(2-Methanesulfonyl-pyrimidin-4-yl)-5-pyridin-3-yl-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine; heart disease, diabetes, Alzheimer's disease, immunodeficiency disorders, inflammatory diseases, hypertension, allergic diseases, autoimmune diseases, destructive bone disorders | VERTEX PHARMACEUTICALS INCORPORATED | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176763-A1 | Azaindoles useful as inhibitors of JAK and other protein kinases | JAK3, JAK2, JAK1 | DYRK1A 461/4885CLK1 894/4885PIK3CA 125/4885 |
| US-20070043063-A1 | Such as 3-(2-Methanesulfonyl-pyrimidin-4-yl)-5-pyridin-3-yl-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine; heart disease, diabetes, Alzheimer's disease, immunodeficiency disorders, inflammatory diseases, hypertension, allergic diseases, autoimmune diseases, destructive bone disorders | LCK, PDXK, CHUK | DYRK1A 488/4885CLK1 998/4885PIK3CA 61/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.